ACLX241220C100000
- 2.85
- 0.000.00%
Arcellx Newsroom
Buy Rating for Arcellx Inc. Based on Promising Efficacy and Safety of BCMA CAR-T Therapy in IMMagine-1 Study
Morgan Stanley Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $111
Truist Financial Initiates Arcellx(ACLX.US) With Buy Rating
A Quick Look at Today's Ratings for Arcellx(ACLX.US), With a Forecast Between $111 to $122
Arcellx Inc (ACLX) Gets a Buy From Truist Financial
Promising Outlook for Arcellx Inc: Anito-cel Therapy Positioned as a Safer Alternative With Strong Market Potential
Arcellx Is Maintained at Buy by UBS
A Quick Look at Today's Ratings for Arcellx(ACLX.US), With a Forecast Between $105 to $133
Express News | Arcellx Inc : UBS Raises Target Price to $114 From $106
Arcellx Price Target Maintained With a $115.00/Share by HC Wainwright & Co.
14 Analysts Have This To Say About Arcellx
Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday
Sector Update: Health Care
Arcellx Inc (ACLX) Gets a Buy From Stifel Nicolaus
TD Cowen Maintains Arcellx(ACLX.US) With Buy Rating
Piper Sandler Maintains Arcellx(ACLX.US) With Buy Rating, Raises Target Price to $115
Analysts Are Bullish on Top Healthcare Stocks: Merus (MRUS), Arcellx Inc (ACLX)
Express News | Arcellx Shares up 6.5% Premarket on Positive Mid-Stage Trial Data for Blood Cancer Cell Therapy
Needham Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $105
Arcellx Inc's Anito-cel Therapy Shows Promising Efficacy and Safety, Analysts Reaffirm Buy Rating